BACE-1 inhibition has the potential to provide a disease-modifying therapy for the treatment of Alzheimer's disease. Optimization of a first generation of BACE-1 inhibitors led to the discovery of novel hydroxyethylamines (HEAs) bearing a tricyclic nonprime side. These derivatives have nanomolar cell potency and are orally bioavailable.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm800138h | DOI Listing |
Publication Analysis
Top Keywords
bace-1 inhibitors
8
second generation
4
generation hydroxyethylamine
4
hydroxyethylamine bace-1
4
inhibitors optimizing
4
optimizing potency
4
potency oral
4
oral bioavailability
4
bioavailability bace-1
4
bace-1 inhibition
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!